Urgent Pharmacy Alert Issued for Ramipril Blood Pressure Medication Recall
Patients across the United Kingdom who rely on Ramipril for managing high blood pressure, heart failure, or kidney disease are being urged to immediately check their medication following an urgent recall announcement. The Medicines and Healthcare products Regulatory Agency has issued a critical alert regarding a specific batch of this widely prescribed drug due to a packaging error that could lead to incorrect dosage consumption.
Manufacturing Error Triggers Precautionary Recall
The MHRA confirmed that Crescent Pharma Limited is recalling one batch of Ramipril 10mg Capsules as a precautionary measure. This action stems from a potential error identified during the secondary packaging process at the manufacturing site. Specifically, inside sealed cartons of Ramipril 10mg Capsules with Batch Number GR174091, some blister packs containing Ramipril 5mg Capsules from Batch GR164094 have been found.
Both product batches were manufactured at the same facility, and the mix-up appears to have occurred during the final packaging stages. The agency has classified this as a Class 2 Patient, Pharmacy and Wholesaler level recall, indicating a significant but not immediately life-threatening risk.
Immediate Actions Required by Healthcare Professionals
Healthcare professionals have been instructed to halt the supply of the affected batch immediately. They must quarantine all remaining stock and return it to their suppliers without delay. Pharmacists and other dispensing professionals are tasked with identifying all patients who received the impacted product between 13 May 2025 and 16 April 2026.
Where batch traceability information is available, they should contact these patients directly to confirm if any remaining stock is in their possession for return. If such data is not accessible, priority should be given to contacting patients dispensed the product most recently, particularly within the last 28 days.
Patient Guidance and Safety Measures
Patients prescribed Ramipril 10mg Capsules are advised to check their medication cartons carefully. The batch number and expiry date information can be found on the outer carton. If the carton contains blister strips labelled as Ramipril 5mg Capsules, individuals should contact their dispensing pharmacy as a first step.
- If the carton contains correctly labelled Ramipril 10mg Capsules, no further action is required.
- Those who are unsure or have questions should seek advice from their pharmacy or healthcare provider.
- Patients should bring the medication leaflet and any remaining capsules when consulting their pharmacy or GP practice.
The MHRA emphasized that while both strengths of Ramipril are used to treat the same conditions, the potential impact of receiving a lower dose is expected to be gradual rather than immediate or life-threatening. However, any adverse reactions or concerns should prompt immediate medical attention.
Reporting and Additional Precautions
Any suspected adverse reactions related to this issue should be reported through the MHRA Yellow Card scheme. The agency noted that the majority of the affected batch was distributed in 2025, meaning many packs may have already been consumed by patients. This recall serves as a critical reminder for medication vigilance and underscores the importance of robust manufacturing and packaging protocols in the pharmaceutical industry.
